•
Dec 31, 2023
Immunome Q4 2023 Earnings Report
Immunome reported full-year 2023 financial results and provided an update on recently acquired assets.
Key Takeaways
Immunome reported its full-year 2023 financial results, highlighting a transformative year marked by the merger with Morphimmune, pipeline advancement, and leadership expansion. The company is focused on developing its existing assets and expanding the pipeline with novel ADCs and RLTs.
Closed the merger with Morphimmune.
Advanced the company's pipeline.
Expanded the company’s leadership team.
Acquired two promising assets and completed a successful financing.